why choose us

300×250 Ad Slot

Research Article: Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629

Date Published: 2023-11-09

Abstract:
At first interim analysis of KEYNOTE-629, health-related quality of life (HRQoL) with pembrolizumab was stable or improved over 48 weeks in recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC). HRQoL results from the second interim analysis in R/M or locally advanced (LA) cSCC are presented.

Introduction:
Cutaneous squamous cell carcinoma (cSCC) is a common type of nonmelanoma skin cancer (NMSC) resulting from uncontrolled proliferation of epidermal keratinocytes [1, 2]. While traditionally considered to account for 20% of cutaneous malignancies, the true incidence of cSCC is largely unknown because it is often excluded from cancer registries or the incidence is reported in combination with basal cell carcinoma as NMSC [1,2,3]. The etiology of cSCC is multifactorial, with the main risk factors including cumulative…

Read more

300×250 Ad Slot